REFERENCES
1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209-49.
2. Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for
3. Mok TSK, Wu YL, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393:1819-30.
4. Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017;377:1919-29.
5. Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168:707-23.
6. Davis AA, Patel VG. The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors. J Immunother Cancer. 2019;7:278.
7. Boothman AM, Scott M, Ratcliffe M, et al. Impact of patient characteristics, prior therapy, and sample type on tumor cell programmed cell death ligand 1 expression in patients with advanced NSCLC screened for the ATLANTIC study. J Thorac Oncol. 2019;14:1390-9.
8. Binnewies M, Roberts EW, Kersten K, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24:541-50.
9. Giustini N, Bazhenova L. Recognizing prognostic and predictive biomarkers in the treatment of non-small cell lung cancer (NSCLC) with immune checkpoint inhibitors (ICIs). Lung Cancer. 2021;12:21-34.
10. Brozos-Vázquez EM, Díaz-Peña R, García-González J, et al. Immunotherapy in nonsmall-cell lung cancer: current status and future prospects for liquid biopsy. Cancer Immunol Immunother. 2021;70:1177-88.
11. Yang Y, Liu H, Chen Y, et al. Liquid biopsy on the horizon in immunotherapy of non-small cell lung cancer: current status, challenges, and perspectives. Cell Death Dis. 2023;14:230.
12. de Miguel-Perez D, Russo A, Arrieta O, et al. Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer. J Exp Clin Cancer Res. 2022;41:186.
13. Champiat S, Dercle L, Ammari S, et al. Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1. Clin Cancer Res. 2017;23:1920-8.
14. Kim HK, Heo MH, Lee HS, et al. Comparison of RECIST to immune-related response criteria in patients with non-small cell lung cancer treated with immune-checkpoint inhibitors. Cancer Chemother Pharmacol. 2017;80:591-8.
15. Tazdait M, Mezquita L, Lahmar J, et al. Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: comparison of RECIST 1.1, irRECIST and iRECIST criteria. Eur J Cancer. 2018;88:38-47.
16. Soria F, Beleni AI, D’Andrea D, et al. Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer. World J Urol. 2018;36:1703-9.
17. Seymour L, Bogaerts J, Perrone A, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18:e143-52.
18. Mulkey F, Theoret MR, Keegan P, Pazdur R, Sridhara R. Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis. J Immunother Cancer. 2020;8:e000146.
19. Nguyen HS, Ho DKN, Nguyen NN, Tran HM, Tam KW, Le NQK. Predicting EGFR mutation status in non-small cell lung cancer using artificial intelligence: a systematic review and meta-analysis. Acad Radiol. 2023:S1076-6332(23)00179-4.
21. Liu Z, Wang S, Dong D, et al. The applications of radiomics in precision diagnosis and treatment of oncology: opportunities and challenges. Theranostics. 2019;9:1303-22.
22. Dercle L, McGale J, Sun S, et al. Artificial intelligence and radiomics: fundamentals, applications, and challenges in immunotherapy. J Immunother Cancer. 2022;10:e005292.
23. Shur JD, Doran SJ, Kumar S, et al. Radiomics in oncology: a practical guide. Radiographics. 2021;41:1717-32.
24. Valentinuzzi D, Vrankar M, Boc N, et al. [18F]FDG PET immunotherapy radiomics signature (iRADIOMICS) predicts response of non-small-cell lung cancer patients treated with pembrolizumab. Radiol Oncol. 2020;54:285-94.
25. Léger MA, Routy B, Juneau D. FDG PET/CT for evaluation of immunotherapy response in lung cancer patients. Semin Nucl Med. 2022;52:707-19.
26. Kaira K, Higuchi T, Naruse I, et al. Metabolic activity by (18)F-FDG-PET/CT is predictive of early response after nivolumab in previously treated NSCLC. Eur J Nucl Med Mol Imaging. 2018;45:56-66.
27. Seban RD, Rouzier R, Latouche A, et al. Total metabolic tumor volume and spleen metabolism on baseline [18F]-FDG PET/CT as independent prognostic biomarkers of recurrence in resected breast cancer. Eur J Nucl Med Mol Imaging. 2021;48:3560-70.
28. Pellegrino S, Fonti R, Mazziotti E, et al. Total metabolic tumor volume by 18F-FDG PET/CT for the prediction of outcome in patients with non-small cell lung cancer. Ann Nucl Med. 2019;33:937-44.
29. Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359:91-7.
30. Castello A, Rossi S, Mazziotti E, Toschi L, Lopci E. Hyperprogressive Disease in patients with non-small cell lung cancer treated with checkpoint inhibitors: the role of (18)F-FDG PET/CT. J Nucl Med. 2020;61:821-6.
31. Polverari G, Ceci F, Bertaglia V, et al. (18)F-FDG pet parameters and radiomics features analysis in advanced nsclc treated with immunotherapy as predictors of therapy response and survival. Cancers. 2020;12:1163.
32. Wu X, Huang Y, Zhao Q, et al. PD-L1 expression correlation with metabolic parameters of FDG PET/CT and clinicopathological characteristics in non-small cell lung cancer. EJNMMI Res. 2020;10:51.
33. Bak SH, Park H, Sohn I, Lee SH, Ahn MJ, Lee HY. Prognostic impact of longitudinal monitoring of radiomic features in patients with advanced non-small cell lung cancer. Sci Rep. 2019;9:8730.
34. Khorrami M, Prasanna P, Gupta A, et al. Changes in CT radiomic features associated with lymphocyte distribution predict overall survival and response to immunotherapy in non-small cell lung cancer. Cancer Immunol Res. 2020;8:108-19.
35. Gillies RJ, Kinahan PE, Hricak H. Radiomics: images are more than pictures, they are data. Radiology. 2016;278:563-77.
36. Clarke LP, Nordstrom RJ, Zhang H, et al. The quantitative imaging network: NCI’s historical perspective and planned goals. Transl Oncol. 2014;7:1-4.
37. Han T, Wu J, Luo W, Wang H, Jin Z, Qu L. Review of generative adversarial networks in mono- and cross-modal biomedical image registration. Front Neuroinform. 2022;16:933230.
38. Rios Velazquez E, Aerts HJ, Gu Y, et al. A semiautomatic CT-based ensemble segmentation of lung tumors: comparison with oncologists’ delineations and with the surgical specimen. Radiother Oncol. 2012;105:167-73.
39. Hosny A, Aerts HJ, Mak RH. Handcrafted versus deep learning radiomics for prediction of cancer therapy response. Lancet Digit Health. 2019;1:e106-7.
40. Zhao P, Li C, Rahaman MM, et al. A comparative study of deep learning classification methods on a small environmental microorganism image dataset (EMDS-6): from convolutional neural networks to visual transformers. Front Microbiol. 2022;13:792166.
41. Zwanenburg A, Vallières M, Abdalah MA, et al. The image biomarker standardization initiative: standardized quantitative radiomics for high-throughput image-based phenotyping. Radiology. 2020;295:328-38.
42. Liu Y, Wu M, Zhang Y, et al. Imaging biomarkers to predict and evaluate the effectiveness of immunotherapy in advanced non-small-cell lung cancer. Front Oncol. 2021;11:657615.
43. Cousin F, Louis T, Dheur S, et al. Radiomics and delta-radiomics signatures to predict response and survival in patients with non-small-cell lung cancer treated with immune checkpoint inhibitors. Cancers. 2023;15:1968.
44. Tunali I, Tan Y, Gray JE, et al. Hypoxia-related radiomics and immunotherapy response: a multicohort study of non-small cell lung cancer. JNCI Cancer Spectr. 2021:5.
45. Tunali I, Gray JE, Qi J, et al. Novel clinical and radiomic predictors of rapid disease progression phenotypes among lung cancer patients treated with immunotherapy: an early report. Lung Cancer. 2019;129:75-9.
46. Sun R, Limkin EJ, Vakalopoulou M, et al. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. Lancet Oncol. 2018;19:1180-91.
47. Vaidya P, Bera K, Patil PD, et al. Novel, non-invasive imaging approach to identify patients with advanced non-small cell lung cancer at risk of hyperprogressive disease with immune checkpoint blockade. J Immunother Cancer. 2020;8:e001343.
48. Korpics MC, Polley MY, Bhave SR, et al. A validated T cell radiomics score is associated with clinical outcomes following multisite SBRT and pembrolizumab. Int J Radiat Oncol Biol Phys. 2020;108:189-95.
49. He B, Dong D, She Y, et al. Predicting response to immunotherapy in advanced non-small-cell lung cancer using tumor mutational burden radiomic biomarker. J Immunother Cancer. 2020;8:e000550.
50. Incoronato M, Aiello M, Infante T, et al. Radiogenomic analysis of oncological data: a technical survey. Int J Mol Sci. 2017;18:805.
51. Stanzione A, Cuocolo R, Ugga L, et al. Oncologic imaging and radiomics: a walkthrough review of methodological challenges. Cancers. 2022;14:4871.
52. Jović A, Brkić K, Bogunović N. A review of feature selection methods with applications. In: Proceedings of the 38th International Convention on Information and Communication Technology, Electronics and Microelectronics (MIPRO): IEEE; 2015 May 25-29; Opatija, Croatia. pp. 1200-5.
53. Nguyen LH, Holmes S. Ten quick tips for effective dimensionality reduction. PLoS Comput Biol. 2019;15:e1006907.
54. Avanzo M, Wei L, Stancanello J, et al. Machine and deep learning methods for radiomics. Med Phys. 2020;47:e185-202.
55. Choy G, Khalilzadeh O, Michalski M, et al. Current applications and future impact of machine learning in radiology. Radiology. 2018;288:318-28.
56. Hajian-Tilaki K. Receiver operating characteristic (ROC) curve analysis for medical diagnostic test evaluation. Caspian J Intern Med. 2013;4:627-35.
57. Park SH, Han K. Methodologic guide for evaluating clinical performance and effect of artificial intelligence technology for medical diagnosis and prediction. Radiology. 2018;286:800-9.
58. Lambin P, Leijenaar RTH, Deist TM, et al. Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol. 2017;14:749-62.
59. Park JE, Kim D, Kim HS, et al. Quality of science and reporting of radiomics in oncologic studies: room for improvement according to radiomics quality score and TRIPOD statement. Eur Radiol. 2020;30:523-36.
60. Sollini M, Antunovic L, Chiti A, Kirienko M. Towards clinical application of image mining: a systematic review on artificial intelligence and radiomics. Eur J Nucl Med Mol Imaging. 2019;46:2656-72.
61. MO, Kirca O, Gunduz S, Ozdogan M. Hyperprogression after immunotherapy: a comprehensive review. J BUON 2019;24:2232-41. Available from: https://napier-repository.worktribe.com/output/2452554/hyperprogression-after-immunotherapy-a-comprehensive-review [Last accessed on 3 Aug 2023].
62. Sehgal K. Hyperprogression in patients with cancer receiving immune checkpoint inhibitors. JAMA Netw Open. 2021;4:e211839.
63. Reinstein ZZ, Pamarthy S, Sagar V, et al. Overcoming immunosuppression in bone metastases. Crit Rev Oncol Hematol. 2017;117:114-27.
64. Ladwa R, Roberts KE, O’Leary C, Maggacis N, O’Byrne KJ, Miles K. Computed tomography texture analysis of response to second-line nivolumab in metastatic non-small cell lung cancer. Lung Cancer Manag. 2020;9:LMT38.
65. Mu W, Tunali I, Gray JE, Qi J, Schabath MB, Gillies RJ. Radiomics of (18)F-FDG PET/CT images predicts clinical benefit of advanced NSCLC patients to checkpoint blockade immunotherapy. Eur J Nucl Med Mol Imaging. 2020;47:1168-82.
66. Ravanelli M, Agazzi GM, Milanese G, et al. Prognostic and predictive value of histogram analysis in patients with non-small cell lung cancer refractory to platinum treated by nivolumab: a multicentre retrospective study. Eur J Radiol. 2019;118:251-6.
67. Trebeschi S, Drago SG, Birkbak NJ, et al. Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers. Ann Oncol. 2019;30:998-1004.
68. Dercle L, Fronheiser M, Lu L, et al. Identification of non-small cell lung cancer sensitive to systemic cancer therapies using radiomics. Clin Cancer Res. 2020;26:2151-62.
69. Nardone V, Tini P, Pastina P, et al. Radiomics predicts survival of patients with advanced non-small cell lung cancer undergoing PD-1 blockade using Nivolumab. Oncol Lett. 2020;19:1559-66.
70. Zhu Z, Chen M, Hu G, et al. A pre-treatment CT-based weighted radiomic approach combined with clinical characteristics to predict durable clinical benefits of immunotherapy in advanced lung cancer. Eur Radiol. 2023;33:3918-30.
71. Tian P, He B, Mu W, et al. Assessing PD-L1 expression in non-small cell lung cancer and predicting responses to immune checkpoint inhibitors using deep learning on computed tomography images. Theranostics. 2021;11:2098-107.
72. Yoon J, Suh YJ, Han K, et al. Utility of CT radiomics for prediction of PD-L1 expression in advanced lung adenocarcinomas. Thorac Cancer. 2020;11:993-1004.
73. Yang B, Zhou L, Zhong J, et al. Combination of computed tomography imaging-based radiomics and clinicopathological characteristics for predicting the clinical benefits of immune checkpoint inhibitors in lung cancer. Respir Res. 2021;22:189.
74. Bouhamama A, Leporq B, Faraz K, et al. Radiomics combined with transcriptomics to predict response to immunotherapy from patients treated with PD-1/PD-L1 inhibitors for advanced NSCLC. Fron Radiol. 2023;3:1168448.
75. Jiang M, Sun D, Guo Y, et al. Assessing PD-L1 expression level by radiomic features from PET/CT in nonsmall cell lung cancer patients: an initial result. Acad Radiol. 2020;27:171-9.
76. Liu C, Gong J, Yu H, Liu Q, Wang S, Wang J. A CT-Based radiomics approach to predict nivolumab response in advanced non-small-cell lung cancer. Front Oncol. 2021;11:544339.
77. Shen L, Fu H, Tao G, Liu X, Yuan Z, Ye X. Pre-immunotherapy contrast-enhanced CT texture-based classification: a useful approach to non-small cell lung cancer immunotherapy efficacy prediction. Front Oncol. 2021;11:591106.
